Application of bergenin in preparation of medicine for treating severe sepsis of whole body
阅读说明：本技术 岩白菜素在制备治疗全身重症脓毒症药物中的用途 (Application of bergenin in preparation of medicine for treating severe sepsis of whole body ) 是由 郝智慧 候冉冉 李秋 孙卓建 杨芬芳 于 2019-12-06 设计创作，主要内容包括：本发明提供了一种岩白菜素在制备治疗全身重症脓毒症药物中的用途,属于生物医药技术领域,本发明的发明人发现,岩白菜素能够通过抑制血清中重症脓毒症引起的TNF-α,IL-6升高和IL-10降低；抑制肝脏中重症脓毒症引起的TNF-α,IL-6升高和IL-10降低；抑制肺脏中重症脓毒症引起的TNF-α,IL-6升高和IL-10降低；抑制脾脏中重症脓毒症引起的TNF-α,IL-6升高和IL-10降低来改善和治疗重症脓毒症。其次,岩白菜素能够通过降低重症脓毒症引起的肺损伤,以及抑制重症脓毒症导致的ERK1/2、JNK和p38的磷酸化程度升高和IκB和NF-κB的磷酸化程度升高来改善和治疗重症脓毒症。因此,岩白菜素可以作为制备治疗全身重症脓毒症相关疾病的潜在药物。(The invention provides an application of bergenin in preparing a medicine for treating severe sepsis, which belongs to the technical field of biological medicines, and the inventor of the invention finds that the bergenin can inhibit the increase of TNF- α -6 and the reduction of IL-10 caused by severe sepsis in serum, inhibit the increase of TNF- α -6 and the reduction of IL-10 caused by severe sepsis in liver, inhibit the increase of TNF- α -6 and the reduction of IL-10 caused by severe sepsis in lung, and inhibit the increase of TNF- α -6 and the reduction of IL-10 caused by severe sepsis in spleen to improve and treat severe sepsis.)
1. The application of bergenin in preparing medicine for treating severe sepsis of whole body is provided.
2. The application of bergenin in preparing medicine for treating liver severe sepsis is provided.
3. The application of bergenin in preparing medicine for treating severe sepsis of lung is provided.
4. The application of bergenin in preparing medicine for treating spleen severe sepsis is provided.
5. Use according to any one of claims 1 to 4, wherein the use comprises use of bergenin to ameliorate the decrease in cell survival caused by severe sepsis.
6. The use according to any one of claims 1 to 4, wherein the use comprises using bergenin to inhibit the increase in TNF- α -6 and decrease in IL-10 in serum caused by severe sepsis, using bergenin to inhibit the increase in TNF- α -6 and decrease in IL-10 in liver caused by severe sepsis, using bergenin to inhibit the increase in TNF- α -6 and decrease in IL-10 in lung caused by severe sepsis, and using bergenin to inhibit the increase in TNF- α -6 and decrease in IL-10 in spleen caused by severe sepsis.
7. Use according to any one of claims 1-4, wherein the use comprises the use of bergenin for reducing lung damage caused by severe sepsis.
8. Use according to any one of claims 1 to 4, wherein the use comprises the use of bergenin to inhibit increased phosphorylation of ERK1/2, JNK and p38 in severe sepsis.
9. Use according to any one of claims 1 to 4, wherein the use comprises the use of bergenin to inhibit increased phosphorylation of I κ B and NF- κ B from severe sepsis.
10. Use according to any one of claims 1 to 4, wherein bergenin is in admixture with a pharmaceutically acceptable carrier for the manufacture of a medicament for the treatment of systemic sepsis.
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of bergenin in preparing a medicine for treating severe sepsis of the whole body.
Background
Sepsis is a serious life-threatening medical condition that manifests itself primarily as a life-threatening multiple organ dysfunction caused by an immune response that is dysregulated by infection. Sepsis is an excessive inflammatory response caused by irritation of the body due to the rapid proliferation of various pathogenic bacteria into the body's blood system and the production of large amounts of toxins.
Severe sepsis is one of sepsis, and compared with general inflammation and sepsis, severe sepsis is extremely serious and the fatality rate of patients is high, and at present, the main difficulty in treating severe sepsis is difficult diagnosis and treatment. Until now, no effective treatment method specially aiming at severe sepsis exists, so that the research and development of new medicaments for treating severe sepsis is a problem which needs to be solved urgently at present.
Bergenin (Bm) is an isocoumarin compound obtained by separating Bergenin monohydrate from bergenia plant of Saxifragaceae; the molecular formula is C14H16O9Molecular weight of 328.27, CAS No.477-90-7, and structural formula as follows:
rhizoma Seu herba Bergeniae has antipyretic, analgesic, antitussive, expectorant, kidney protecting, antidiabetic, HIV resisting, and anticoagulant effects. However, the therapeutic effect of bergenin on severe sepsis and the related mechanism research thereof are not reported yet.
Disclosure of Invention
The invention aims to enrich the medical application of bergenin and provide the application of bergenin in preparing a medicine for treating severe sepsis aiming at the problem of insufficient treatment of severe sepsis in the prior art.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention provides application of bergenin in preparing a medicine for treating severe sepsis of the whole body.
In addition, the invention provides application of bergenin in preparing a medicine for treating severe liver sepsis.
In addition, the invention provides application of bergenin in preparing a medicine for treating severe sepsis of lungs.
In addition, the invention provides application of bergenin in preparation of a medicine for treating severe spleen sepsis.
Preferably, the use comprises use of bergenin to ameliorate the decrease in cell survival caused by severe sepsis.
Preferably, the use comprises inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in serum by using bergenin, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in liver by using bergenin, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in lung by using bergenin, and inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in spleen by using bergenin.
Preferably, the use comprises the use of bergenin to reduce lung damage caused by severe sepsis.
Preferably, the use comprises use of bergenin to inhibit increased phosphorylation of ERK1/2, JNK and p38 caused by severe sepsis.
Preferably, the use comprises use of bergenin to inhibit increased phosphorylation of I κ B and NF- κ B resulting from severe sepsis.
Preferably, the bergenin can be mixed with a pharmaceutically acceptable carrier for preparing a medicament for treating systemic sepsis.
The invention has the beneficial effects that:
1. the invention provides a new application of bergenin and provides a new treatment mode for treating severe sepsis patients.
2. The invention proves that the bergenin can improve and treat severe sepsis by inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in serum, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in liver by using the bergenin, inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in lung by using the bergenin, and inhibiting the increase of TNF- α -6 and the decrease of IL-10 caused by severe sepsis in spleen by using the bergenin.
3. The invention proves that bergenin can improve and treat severe sepsis by reducing lung injury caused by severe sepsis and inhibiting the increase of phosphorylation degrees of ERK1/2, JNK and p38 and the increase of phosphorylation degrees of I kappa B and NF-kappa B caused by severe sepsis.
4. The bergenin is derived from bergenia purpurascens extract, has low toxicity and good therapeutic effect, and can reduce antibiotic usage when used for treating sepsis.
Drawings
FIG. 1 Effect of bergenin on cell survival.
FIG. 2 Effect of bergenin on inflammatory cytokine secretion in LPS challenged RAW264.7 cells.
FIG. 3 Effect of bergenin on the secretion of inflammatory cytokines in the serum of LPS challenged C57 mice.
FIG. 4 Effect of bergenin on the secretion of inflammatory cytokines in the liver of LPS challenged C57 mice.
FIG. 5 Effect of bergenin on inflammatory cytokine secretion in the spleen of LPS challenged C57 mice.
FIG. 6 Effect of bergenin on inflammatory cytokine secretion in the lungs of LPS challenged C57 mice.
FIG. 7 Effect of bergenin on lung pathology in LPS infected mice.
(A) Blank group TNF- α (B) LPS group TNF- α (C) bergenia group TNF- α
(D) Blank IL-10 (E) LPS group IL-10 (F) bergenia group IL-10
FIG. 8 effect of bergenin on MAPK and NF-. kappa.B pathway status in LPS-infected C57 mouse lung histones.
(A) Effect of bergenin on p38, ERK and JNK phosphorylation in lung histones of LPS-infected C57 mice. (B) Effect of bergenin on phosphorylation of I κ B and NF- κ B in lung histones of LPS-infected C57 mice.
Detailed Description
In order to clearly illustrate the technical features of the present solution, the present solution is explained below by way of specific embodiments.